https://orcid.org/0000-0001-6523-7621
References
- Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015;373(16):1541–1552.
- Duval M, Suciu S, Ferster A, et al. Comparison of Escherichia coli-asparaginase with erwinia-asparaginase in the treatment of childhood lymphoid malignancies. Blood. 2002;99(8):2734–2739.
- Pegaspargase (Oncaspar ®) (package insert). Lexington (MA): Baxalta US Inc; 2017.
- Panetta JC, Gajira A, Hak LJ, et al. Comparison of native E.coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric ALL. CPT. 2009;24(5):393–397.
- Burke P, Aldoss I, Lunning M, et al. Pegaspargase-related high-grade hepatotoxicity in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not predict recurrent hepatotoxicity with subsequent doses. Leuk Res. 2018;66:49–56.
- Aldoss I, Douer D, Behrendt CE, et al. Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia. Eur J Haematol. 2016;96(4):375–380.
- Alshiekh-Nasany R, Douer D. L-carnitine for treatment of pegasparaginase-induced hepatotoxicity. Acta Haematol. 2016;135(4):208–210.
- Levocarnitine (Carnitor ®) (package insert). Gaithersburg (MD): Leadiant Biosciences; 2018.
- Al-Nawakil C, Willems L, Mauprivez C, et al. Successful treatment of L-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors. Leuk Lymphoma. 2014;55(7):1670–1674.
- Blackman A, Boutin A, Shimanovsky A, et al. Levocarnitine and vitamin B complex for the treatment of pegaspargase-induced hepatotoxicity: a case report and review of the literature. J Oncol Pharm Pract. 2018;24(5):393–397.